AbbVie Inc. (ABBV): Price and Financial Metrics
AbbVie Inc. (ABBV)
Today's Latest Price: $90.11 USD
Updated Sep 18 7:00pm
Add ABBV to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 232 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABBV Stock Summary
- ABBV has a higher market value than 99.03% of US stocks; more precisely, its current market capitalization is $159,029,123,797.
- ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 0.59% of US stocks.
- In terms of volatility of its share price, ABBV is more volatile than only 4.19% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to AbbVie Inc, a group of peers worth examining would be AMGN, AZN, LLY, CSCO, and NVO.
- Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to www.abbvie.com.
ABBV Stock Price Chart Technical Analysis Charts
ABBV Price/Volume Stats
| Current price | $90.11 | 52-week high | $101.28 |
| Prev. close | $89.63 | 52-week low | $62.55 |
| Day low | $88.86 | Volume | 10,076,304 |
| Day high | $90.50 | Avg. volume | 10,025,920 |
| 50-day MA | $94.66 | Dividend yield | 5.24% |
| 200-day MA | $89.17 | Market Cap | 159.03B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
ABBV Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $90.11 | $229.97 | 157% |
Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 66th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 158% on a DCF basis. The most interesting components of our discounted cash flow analysis for AbbVie Inc ended up being:
- The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 22.77% of free cash flow generating stocks in the Healthcare sector.
- AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 6.07% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 152% |
| 1% | 154% |
| 2% | 157% |
| 3% | 159% |
| 4% | 162% |
| 5% | 164% |
Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See QDEL, HZNP, LXRX, HCSG, and AHPI.
Loading social stream, please wait...